Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM0306 in IgG4-Related Disease
NCT07621939Phase 3Not yet recruiting
- Sponsor
- ImmuneOnco
- Start
- Jul 2026
- Primary completion
- May 2030
01
Overview
Phase 3, randomised, double-blind trial of IMM0306S in IgG4-related disease (IgG4-RD) (3 arms), sponsored by ImmuneOnco. Primary endpoint: Time to disease relapse at 52 weeks. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
IMM0306S
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on NCT07621939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07621939.